Santos M.F., Almorox R.B., Solan L., Lopez O., Gallardo A., Garcia-Avila S., Esquirol A., Ferra C., Martin A., Garcia A., Perez E., Colorado M., Cortes M., Cabrero M., Gayoso J., Yañez L., Pascual M.J., Heras I.D.L., Diez J.L., Caballero M.D., Kwon M., Corral L.L.. CT-275 Incidence and Characteristics of Chronic GVHD in Haploidentical Stem-Cell Transplantation With Post-Transplantation Cyclophosfamide: Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC). Clinical Lymphoma Myeloma & Leukemia. 2022; 22DOI:10.1016/S2152-2650(22)01659-7. PMID:36164212. IF:(Q/D).

Munir T., Moreno C., Owen C., Follows G., Benjamini O., Janssens A., Levin M.-D., Osterborg A., Robak T., Simkovic M., Stevens D., Voloshin S., Vorobyev V., Yagci M., Ysebaert L., Qi Q., Steele A., Schuier N., Baeten K., Caces D.B., Niemann C., Kater A.. CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study. Clinical Lymphoma Myeloma & Leukemia. 2022; 22DOI:10.1016/S2152-2650(22)01322-2. PMID:36163867. IF:(Q/D).

Moreno C., Greil R., Demirkan F., Tedeschi A., Anz B., Larratt L., Simkovic M., Novak J., Strugov V., Gill D., Gribben J.G., Kwei K., Dai S., Hsu E., Dean J.P., Flinn I.W.. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. HAEMATOLOGICA. 2022; 107(9)DOI:10.3324/haematol.2021.279012. PMID:35021599. IF:10.100(Q1/2D).

Bazarbachi A., Boumendil A., Finel H., Khvedelidze I., Romejko-Jarosinska J., Tanase A., Akhtar S., Ben Othman T., Ma’koseh M., Afanasyev B., El-Cheikh J., Briones J., Gülbas Z., Hamladji R.-M., Elverdi T., Blaise D., Martínez C., Alma E., Halaburda K., Sousa A.B., Glass B., Robinson S., Montoto S., Sureda A.. Correction: The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years (Leukemia, (2022), 36, 6, (1646-1653), 10.1038/s41375-022-01563-8). LEUKEMIA. 2022; 36(8)DOI:10.1038/s41375-022-01639-5. PMID:35840758. IF:11.400(Q1/1D).

Barr P.M., Owen C., Robak T., Tedeschi A., Bairey O., Burger J.A., Hillmen P., Coutre S.E., Dearden C., Grosicki S., McCarthy H., Li J.-Y., Offner F., Moreno C., Zhou C., Hsu E., Szoke A., Kipps T.J., Ghia P.. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Advances. 2022; 6(11)DOI:10.1182/bloodadvances.2021006434. PMID:35377947. IF:7.500(Q1/2D).

Meijide J.B.. Medicina de precisión en leucemia linfática crónica: Análisis de coste-efectividad de nuevas combinaciones dirigidas. Farmacia Hospitalaria. 2022; 46(3)DOI:10.7399/fh.13280. PMID:36183201. IF:(Q/D).

Gutiérrez-Hernández, MD, Ramil, G, González-Alvarez, N, San-José, P. Reticulocyte Count Interference at the Onset of Acute Myeloid Leukemia. International Journal of Laboratory Hematology. 2025; 47(6)DOI:10.1111/ijlh.14545. PMID:40836604. IF:2.300(Q2/5D).

Torrent, A, Morgades, M, Iacoboni, G, Reguera, JL, Kwon, M, Corral, LL, Hernani, R, Ortiz-Maldonado, V, Sanz, J, Gonzalez, ACC, Guerra, L, Pina, JMS, Mussetti, A, Garcia-Sancho, AM, Bastos-Oreiro, M, Delgado, J, Carpio, C, Sancho, JM, Perez-Martinez, A, Barba, P. Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy. BONE MARROW TRANSPLANTATION. 2025; 60(12)DOI:10.1038/s41409-025-02722-y. PMID:41028300. IF:5.200(Q1/1D).